Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS

SBMP - disrupting the manufacturing of biological drugs through a ground-breaking nanotechnology-based microcarrier

Project description

Nanofibre-based microcarriers designed to revolutionise novel biological drugs production

Biologics have revolutionised the way we treat many diseases in a variety of fields. Over the last years, cell and gene therapies have proven that they can provide remarkable outcomes for patients. These novel modalities challenge traditional ways of manufacturing, resulting in an unprecedented need for disruptive and flexible technologies. Funded by the European Innovation Council, the SBMP-microcarrier project is introducing a game-changing, green, sustainable, deep-tech innovation for the biopharmaceutical industry. The nanofibre-based platform allows for industrial-scale production of microcarriers with unparalleled surface area for cell growth, reproducibility and customisation. SBMP-microcarrier products are scalable from laboratory testing to large-scale production of novel classes of biological therapies, including cell and gene therapies, and vaccines.

Objective

Cellevate proposes a completely novel type of nanofibrous microcarriers for adherent cell culture in bioreactors based on the proprietary Superior Biologics Manufacturing Platform (SBMP). It is a game-changing deep-tech innovation for the biopharmaceutical industry. SBPM-microcarriers
are highly customizable, faithfully replicate the 3D extracellular environment found in the human body, and provide a 60 times larger area for cell growth compared to competitive solutions. The unique scaffold properties are a result of a patent-pending nanofiber scaffold production
technology (PCT/EP2020/081958) which creates networks of polymer nanofibers that can be handled in a liquid form, unachievable by competing solutions. By offering high yields and ensuring the optimal conditions for human cell growth, SBMP-microcarriers have the potential to transform the
biopharmaceutical market by pushing the limits of today’s biological drugs production to an unachievable level of quality and efficiency.

Coordinator

CELLEVATE AB
Net EU contribution
€ 2 485 857,50
Address
MEDICON VILLAGE, SCHEELETORGET 1
223 81 LUND
Sweden

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Södra Sverige Sydsverige Skåne län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 551 225,00